Virtual Library
Start Your Search
C. Shin
Author of
-
+
P2.06 - Poster Session/ Screening and Early Detection (ID 219)
- Event: WCLC 2015
- Type: Poster
- Track: Screening and Early Detection
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.06-027 - Pleural Fluid Reactive Oxygen Species Modulator 1 (Romo1) as a Diagnostic and Prognostic Marker in Lung Cancer Patients with Malignant Effusion (ID 800)
09:30 - 09:30 | Author(s): C. Shin
- Abstract
Background:
Reactive oxygen species modulator 1 (Romo1) is a novel protein that is critical in mitochondrial reactive oxygen species (ROS) generation. It is increased in most cancer cell lines and is associated with resistance to chemotherapy in vitro. Recently, serum Romo1 has been suggested as a potential diagnostic marker for non-small cell lung cancer (NSCLC), and increased tissue Romo1 protein expression has been related with poor prognosis in patients following surgical resection for NSCLC. The clinical significance of pleural fluid Romo1 is unknown. We evaluated the clinical usefulness of pleural fluid Romo1 as a potential diagnostic and prognostic marker in patients with lung cancer-associated malignant effusion.
Methods:
Romo1 level was measured in pleural fluid using enzyme-linked immunosorbent assay in four groups: lung cancer-associated malignant effusion (n =24; 15 adenocarcinomas, 7 squamous cell carcinomas and 2 small cell lung cancers), tuberculous pleurisy (n = 14), parapneumonic effusion (n =15) and transudative effusion (n = 16). The discriminative power in lung cancer-associated malignant effusion and the association with survival of Romo1 was determined using receiver operating characteristic (ROC) curve and Kaplan-Meier survival analysis, respectively.
Results:
Pleural fluid Romo1 level was significantly higher in lung cancer-associated malignant effusion compared with other groups (all p < 0.001). In the ROC curve analysis, the optimal cutoff value for lung cancer-associated malignant effusion was 451.5 pg/mL with a sensitivity of 81.9% and specificity of 84.8%, with an area under the curve of 0.838 (95% confidence interval : 0.789 - 0892, p < 0.01). In addition, at the cutoff determined by median Romo1 level, high Romo1 expression was related with reduced overall survival in patients with NSCLC (p = 0.03). For all patients, pleural fluid Romo1 level was not related with age, gender, smoking status, tumor differentiation, histological type, glucose, protein, albumin and lactate dehydrogenase level.
Conclusion:
Romo1 discriminated lung cancer-associated malignant effusion from non-malignant effusions with considerable sensitivity and specificity. Also, high Romo1 level was associated with poor prognosis in lung cancer patients. Pleural fluid Romo1 could be a potential diagnostic and prognostic marker in patients with lung cancer-associated malignant effusion.
